Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier B.V.
Abstract
Background: Few published studies addressed real-world clinical experience with fingolimod especially in the Middle East region. Objective: To review our clinical experience with fingolimod at a specialized academic MS center in Lebanon. Methods: All patients treated with fingolimod at the MS Center between October 2011 and January 2015 were retrospectively identified. Results: A total of 122 patients were included. The first dose observation was uneventful in 98.8% of patients. Annualized relapse rate decreased from 1.16 pre-treatment to 0.29 post-treatment representing a relative risk reduction of 75% (p < 0.0001). The proportion of patients with no new T2 or enhancing lesions was 66.3%. Seventy-six (62.3%) patients experienced adverse events with lymphopenia, increase liver enzymes, urinary tract infections and fatigue being the most common. Conclusion: Our cohort confirms the effectiveness and safety of fingolimod in a real world setting. © 2015 Elsevier B.V..
Description
Keywords
Clinical, Efficacy, Fingolimod, Lebanon, Middle east, Multiple sclerosis, Adult, Cohort studies, Disability evaluation, Female, Fingolimod hydrochloride, Humans, Immunosuppressive agents, Male, Middle aged, Immunosuppressive agent, Article, Brain damage, Clinical practice, Cohort analysis, Drug efficacy, Drug safety, Drug tolerance, Drug withdrawal, Fatigue, Herpes virus infection, Herpes zoster, Human, Hypertransaminasemia, Low drug dose, Lymphocytopenia, Major clinical study, Priority journal, Radiculitis, Relapse, Respiratory tract infection, Retrospective study, Risk reduction, Treatment duration, Urinary tract infection, Disability